Furthermore, we performed experiments including RNA pull-down assays, mass spectroscopy, analyses of a TMA constructed from surgical specimens, qPCR analysis of specimens of different clinicopathological stages, and western blot to evaluate YBX3 protein expression in HEIH-knockdown cell lines to comprehensively evaluate lncRNA-HEIH/YBX3 as a biomarker for diagnosis and prognosis across cancers and as a promising molecular target for colon adenocarcinoma (COAD). This evidence concerns the gene HEIH and cancer.